Although it has previously been shown that targeting HGF or c-Met expression using ribozyme radiosensitizers in GBM cells in vitro and xenograft tumor in vivo [10], demonstration of clinically useful inhibitors of the tyrosine kinase activity of c-Met combined with radiation have not been previously tested in GBM models. The gene discussed is MET; the disease is neoplasm.